{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:47:32Z","timestamp":1778888852550,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bioorg.2022.106071","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T11:10:40Z","timestamp":1659352240000},"page":"106071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Novel pyrazolo[3,4-d]pyrimidines as dual Src\/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment"],"prefix":"10.1016","volume":"128","author":[{"given":"Salvatore","family":"Di Maria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Picarazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Cianciusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuele","family":"Crespan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Perini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Sabetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serenella","family":"Deplano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Poggialini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Maccioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Maga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Schenone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Dreassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2022.106071_b0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/stem.180399","article-title":"Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia","volume":"18","author":"Kabarowski","year":"2000","journal-title":"Stem Cells"},{"key":"10.1016\/j.bioorg.2022.106071_b0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2022.106071_b0015","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2022.106071_b0020","doi-asserted-by":"crossref","unstructured":"T. O\u2019Hare, M.W.N. Deininger, C.A. Eide, T. Clackson, B.J. Druker, Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia, Clin. Cancer Res. 17 (2011) 212\u2013221, doi: 10.1158\/1078-0432.CCR-09-3314.","DOI":"10.1158\/1078-0432.CCR-09-3314"},{"key":"10.1016\/j.bioorg.2022.106071_b0025","unstructured":"Drug Approval Package: Gleevec (Imatinib Mesylate) NDA #21-335, (n.d.). Available from: <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21335_Gleevec.cfm> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0030","unstructured":"Glivec | European Medicines Agency, (n.d.). Available from: <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glivec#authorisation-details-section> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0035","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2022.106071_b0040","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2022.106071_b0045","unstructured":"Drug Approval Package: Sprycel (Dasatinib) NDA #021986 & 022072, (n.d.). Available from: <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021986_022072_SprycelTOC.cfm> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0050","unstructured":"Sprycel | European Medicines Agency, (n.d.). Available from: <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sprycel#authorisation-details-section> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0055","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4155\/fmc.12.29","article-title":"An update on dual Src\/Abl inhibitors","volume":"4","author":"Musumeci","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0065","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2022.106071_b0070","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1201972","article-title":"Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation","volume":"16","author":"Chaturvedi","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2022.106071_b0075","doi-asserted-by":"crossref","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","article-title":"Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner","volume":"285","author":"Pene-Dumitrescu","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0080","doi-asserted-by":"crossref","unstructured":"T. O\u2019Hare, D.K. Walters, E.P. Stoffregen, T. Jia, P.W. Manley, J. Mestan, S.W. Cowan-Jacob, F.Y. Lee, M.C. Heinrich, M.W.N. Deininger, B.J. Druker, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants, Cancer Res. 65 (2005) 4500\u20134505, doi: 10.1158\/0008-5472.CAN-05-0259.","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"10.1016\/j.bioorg.2022.106071_b0085","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1182\/blood-2019-131694","article-title":"The \u201cGatekeeper\u201d mutation T315I in BCR\/ABL confers additional oncogenic activities to Philadelphia chromosome positive leukemia","volume":"134","author":"Zafar","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2022.106071_b0090","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0095","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","article-title":"Ponatinib: accelerated disapproval","volume":"20","author":"Gainor","year":"2015","journal-title":"Oncologist"},{"issue":"2020","key":"10.1016\/j.bioorg.2022.106071_b0100","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bioorg.2022.106071_b0105","unstructured":"FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing | FDA, (n.d.). Available from: <https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-requires-multiple-new-safety-measures-leukemia-drug-iclusig> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0110","unstructured":"Iclusig | European Medicines Agency, (n.d.). Available from: <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/iclusig#authorisation-details-section> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0115","unstructured":"Drug Approval Package: Tasigna (Nilotinib) NDA #022068, (n.d.). Available from: <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022068toc.cfm> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0120","unstructured":"Drug Approval Package: Brand Name (Generic Name) NDA #, (n.d.). Available from: <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203341_bosulif_toc.cfm> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0125","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1021\/jm400233w","article-title":"Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant","volume":"56","author":"Radi","year":"2013","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2022.106071_b0130","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/ml4000782","article-title":"Pyrazolo[3,4-d]pyrimidine prodrugs: strategic optimization of the aqueous solubility of dual Src\/Abl inhibitors","volume":"4","author":"Vignaroli","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.106071_b0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm5013159","article-title":"Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma","volume":"58","author":"Tintori","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/acsmedchemlett.7b00456","article-title":"Water solubility enhancement of pyrazolo[3,4- d] pyrimidine derivatives via miniaturized polymer-drug microarrays","volume":"9","author":"Sanna","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.106071_b0145","doi-asserted-by":"crossref","DOI":"10.1038\/srep21509","article-title":"Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery","volume":"6","author":"Vignaroli","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2022.106071_b0150","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1021\/acs.jmedchem.7b00637","article-title":"Prodrugs of pyrazolo[3,4-d]pyrimidines: from library synthesis to evaluation as potential anticancer agents in an orthotopic glioblastoma model","volume":"60","author":"Vignaroli","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0155","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1021\/jm1012819","article-title":"Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study","volume":"54","author":"Radi","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0160","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1016\/j.bmcl.2018.09.024","article-title":"Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment","volume":"28","author":"Molinari","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.106071_b0165","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2022.106071_b0170","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2022.106071_b0175","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.bmcl.2011.07.079","article-title":"Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells","volume":"21","author":"Radi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.106071_b0180","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1021\/jm0209580","article-title":"Synthesis, molecular modeling studies, and pharmacological activity of selective A1 receptor antagonists","volume":"45","author":"Bondavalli","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0185","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/co500004e","article-title":"Exploring the chemical space around the privileged pyrazolo[3,4-d]pyrimidine scaffold: toward novel allosteric inhibitors of T315I-mutated Abl","volume":"16","author":"Vignaroli","year":"2014","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.bioorg.2022.106071_b0190","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2133\/dmpk.DMPK-13-RG-094","article-title":"CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction","volume":"29","author":"Zamperini","year":"2014","journal-title":"Drug Metab. Pharmacok."},{"key":"10.1016\/j.bioorg.2022.106071_b0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1747-0285.2009.00905.x","article-title":"Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template","volume":"75","author":"Zhou","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2022.106071_b0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins"},{"key":"10.1016\/j.bioorg.2022.106071_b0205","doi-asserted-by":"crossref","unstructured":"M.A. Young, N.P. Shah, L.H. Chao, M. Seeliger, Z. v. Milanov, W.H. Biggs, D.K. Treiber, H.K. Patel, P.P. Zarrinkar, D.J. Lockhart, C.L. Sawyers, J. Kuriyan, Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680, Cancer Res. 66 (2006) 1007\u20131014, doi: 10.1158\/0008-5472.CAN-05-2788.","DOI":"10.1158\/0008-5472.CAN-05-2788"},{"key":"10.1016\/j.bioorg.2022.106071_b0210","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/ci100436p","article-title":"FRED pose prediction and virtual screening accuracy","volume":"51","author":"McGann","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2022.106071_b0215","doi-asserted-by":"crossref","first-page":"111545","DOI":"10.1016\/j.ejmech.2019.07.048","article-title":"Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines","volume":"181","author":"Fallacara","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0220","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1021\/jm9002928","article-title":"Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc","volume":"52","author":"Getlik","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0225","doi-asserted-by":"crossref","unstructured":"J.S. Tokarski,J.A. Newitt,C.Y. Chang,J.D. Cheng,M. Wittekind,S.E. Kiefer,K. Kish,F.Y. Lee,R. Borzillerri,L.J. Lombardo,D. Xie,Y. Zhang,H.E. Klei. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66 (2006) 5790\u20135797, doi: 10.1158\/0008-5472.CAN-05-4187.","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"10.1016\/j.bioorg.2022.106071_b0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2022.106071_b0235","doi-asserted-by":"crossref","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","article-title":"UniProt: the universal protein knowledgebase","volume":"45","author":"Bateman","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2022.106071_b0240","unstructured":"D.A. Case, I.Y. Ben-Shalom, S.R. Brozell, D.S. Cerutti, T.E. Cheatham, III, V.W.D. Cruzeiro, T.A. Darden, R.E. Duke, D. Ghoreishi, M.K. Gilson, H. Gohlke, A.W. Goetz, D. Greene, R Harris, N. Homeyer, S. Izadi, A. Kovalenko, T. Kurtzman, T.S. Lee, S. LeGrand, P. Li, C. Lin, J. Liu, T. Luchko, R. Luo, D.J. Mermelstein, K.M. Merz, Y. Miao, G. Monard, C. Nguyen, H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, R. Qi, D.R. Roe, A. Roitberg, C. Sagui, S. Schott-Verdugo, J. Shen, C.L. Simmerling, J. Smith, R. Salomon-Ferrer, J. Swails, R.C. Walker, J. Wang, H. Wei, R.M. Wolf, X. Wu, L. Xiao, D.M. York and P.A. Kollman (2018), AMBER 2018, University of California, San Francisco. Available from: <http:\/\/ambermd.org\/contributors.html> (accessed March 11, 2022)."},{"key":"10.1016\/j.bioorg.2022.106071_b0245","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bioorg.2022.106071_b0250","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2022.106071_b0255","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theory Comput."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822004771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822004771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:36:38Z","timestamp":1758616598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822004771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":51,"alternative-id":["S0045206822004771"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106071","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pyrazolo[3,4-d]pyrimidines as dual Src\/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106071"}}